Publication number: 20220112216
Abstract: The present disclosure provides compounds of Formula (I), and salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be useful for inhibiting kinases, e.g., glycogen synthase kinase 3 (GSK3). The provided compounds may be able to selectively inhibit GSK3a, as compared to GSK3P and/or other kinases. The present disclosure further provides pharmaceutical compositions, kits, and methods of use, each of which involve the compounds. The compounds, pharmaceutical compositions, and kits may be useful for treating diseases associated with aberrant activity of GSK3a (e.g., Fragile X syndrome, attention deficit hyperactivity disorder (ADHD), childhood seizure, intellectual disability, diabetes, acute myeloid leukemia (AML), autism, and psychiatric disorder).
Type:
Application
Filed:
October 22, 2021
Publication date:
April 14, 2022
Applicants:
The Broad Institute, Inc., Biogen MA Inc.
Inventors:
Florence Fevrier Wagner, Michel Weiwer, Arthur J. Campbell, Joshua R. Sacher, Edward Holson, Brian Stuart Lucas, TeYu Chen